Volumetric modulated arc therapy treatment planning based on virtual monochromatic images for head and neck cancer: effect of the contrast-enhanced agent on dose distribution

Virtual monochromatic images (VMIs) at a lower energy level can improve image quality but the computed tomography (CT) number of iodine contained in the contrast-enhanced agent is dramatically increased. We assessed the effect of the use of contrast-enhanced agent on the dose distributions in volumetric modulated arc therapy (VMAT) planning for head and neck cancer (HNC). Based on the VMIs at 40 keV (VMI_40keV ), 60 keV(VMI_60keV ), and 77 keV (VMI_77keV ) of a tissue characterization phantom, lookup tables (LUTs) were created. VMAT plans were generated for 15 HNC patients based on contrast-enhanced- (CE-) VMIs at 40-, 60-, and 77 keV using the corresponding LUTs, and the doses were recalculated based on the noncontrast-enhanced- (nCE-) VMIs. For all structures, the difference in CT numbers owing to the contrast-enhanced agent was prominent as the energy level of the VMI decreased, and the mean differences in CT number between CE- and nCE-VMI was the largest for the clinical target volume (CTV) (125.3, 55.9, and 33.1 HU for VMI_40keV , VMI_60keV , and VMI_77keV, respectively). The mean difference of the dosimetric parameters (D_99% , D_50% , D_1% , D_mean , and D_0.1cc ) for CTV and OARs was <1% in the treatment plans based on all VMIs. The maximum difference was observed for CTV in VMI_40keV (2.4%), VMI_60keV (1.9%), and VMI_77keV (1.5%) plans. The effect of the contrast-enhanced agent was larger in the VMAT plans based on the VMI at a lower energy level for HNC patients. This effect is not desirable in a treatment planning procedure.